Development of a whole cell pneumococcal vaccine: BPL inactivation, cGMP production, and stability

Vaccine

Volumn 32, Issue 9, 2014, Pages 1113-1120

  Gonçalves, Viviane M ^a   Dias, Waldely O ^a   Campos, Ivana B ^a,b   Liberman, Celia ^a   Sbrogio Almeida, Maria E ^a   Silva, Eliane P ^a,b   Cardoso, Celso P ^a   Alderson, Mark ^c   Robertson, George ^c   Maisonneuve, Jean François ^c   Tate, Andrea ^c   Anderson, Porter ^d   Malley, Richard ^d   Fratelli, Fernando ^a   Leite, Luciana C C ^a  

^a INSTITUTO BUTANTAN   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c PATH   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

CGMP production; Streptococcus pneumoniae; Whole cell vaccine

Indexed keywords

CGMP PRODUCTION; STREPTOCOCCUS PNEUMONIAE; WHOLE CELL VACCINE;

ANIMALS; ANTIBODIES, BACTERIAL; BIOREACTORS; FEMALE; FERMENTATION; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; MICROBIAL VIABILITY; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PROPIOLACTONE; QUALITY CONTROL;

EID: 84895057176     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.10.091     Document Type: Article

References (23)

1. World Health Organization Pneumococcal conjugate vaccine for childhood immunization - WHO position paper. Wkly Epidemiol Rec 2007, 82:93-104.
2. Bogaert D., De Groot R., Hermans P.W. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis 2004, 4(March (3)):144-154.
3. Kadioglu A., Weiser J.N., Paton J.C., Andrew P.W. The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease. Nat Rev Microbiol 2008, 6(4):288-301.
4. Weiser J.N. The pneumococcus: why a commensal misbehaves. J Mol Med 2010, 88:97-102.
5. World Health Organization The World Health Report 2004 - Changing History 2004, 120-126. WHO, Geneva, Austria.
6. O'Brien K.L., Wolfson L.J., Watt J.P., Henkle E., Deloria-Knoll M., McCall N., et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009, 374(September (9693)):893-902.
7. Lee C.J., Banks S.D., Lee J.P. Virulence, immunity, and vaccine related to Streptococcus pneumoniae. Crit Rev Microbiol 1991, 18(2):89-114.
8. Spika J.S., Facklam R.R., Pikaytis B.D., Oxtoby M.J., Party P.S.W. Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979-1987. J Infect Dis 1991, 163:1273-1278.
9. Liñares J., Ardanuy C., Pallares R., Fenoll A. Changes in antimicrobial resistance, serotypes, and genotypes in Streptococcus pneumoniae over a thirty-year period. Clin Microbiol Infect 2010, 16:402-410.
10. Obaro S.K., Henderson D.C., Monteil M. The pneumococcal problem: a review. BMJ 1996, 312:1521-1525.
11. Alexandre C., Dubos F., Courouble C., Pruvost I., Varon E., Hospital Network for Evaluating the Management of Common Childhood Diseases, Martinot A. Rebound in the incidence of pneumococcal meningitis in northern France: effect of serotype replacement. Acta Paediatrica 2010, 99:1686-1690.
12. Leach A.J., Morris P.S., McCallum G.B., Wilson C.A., Stubbs L., Beissbarth J., et al. Emerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001. BMC Infect Dis 2009, 9:121.
13. Munoz-Almagro C., Jordan I., Gene A., Latorre C., Garcia-Garcia J.J., Pallares R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis 2008, 46(2):174-182.
14. Lipsitch M., Whitney C.G., Zell E., Kaijalainen T., Dagan R., Malley R. Are anticapsular antibodies the primary mechanism of protection against invasive pneumococcal disease?. PLoS Med 2005, 2(January (1)):e15.
15. Malley R., Lipsitch M., Stack A., Saladino R., Fleisher G., Pelton S., Thompson C., Briles D., Anderson P. Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci. Infect Immun 2001, 69:4870-4873.
16. Malley R., Morse S.C., Leite L.C.C., Areas A.P., Ho P.L., Kubrusly F.S., Almeida I.C., Anderson P. Evaluation of adjuvants given intranasally with killed noncapsulated pneumococci in multi-serotype protection of mice against colonization and middle ear infection. Infect Immun 2004, 72:4290-4292.
17. Lu Y.J., Leite L., Gonçalves V.M., Dias W.O., Liberman C., Fratelli F., Alderson M., Tate A., Maisonneuve J.F., Robertson G., Graca R., Sayeed S., Thompson C.M., Anderson P., Malley R. GMP-grade pneumococcal whole-cell vaccine injected subcutaneously protects mice from nasopharyngeal colonization and fatal aspiration-sepsis. Vaccine 2010, 28(47):7468-7475.
18. Lu Y.J., Yadav P., Clements J.D., Forte S., Srivastava A., Thompson C.M., Seid R., Look J., Alderson M., Tate A., Maisonneuve J.F., Robertson G., Anderson P., Malley R. Options for inactivation, adjuvant, and route of topical administration of a killed, unencapsulated pneumococcal whole-cell vaccine. Clin Vaccine Immunol 2010, 17(6):1005-1012.
19. Liberman C., Takagi M., Cabrera-Crespo J., Sbrogio-Almeida M.E., Dias W.O., Leite L.C.C., Gonçalves V.M. Pneumococcal whole-cell vaccine: optimization of cell growth of unencapsulated Streptococcus pneumoniae in bioreactor using animal-free medium. J Ind Microbiol Biotechnol 2008, 35(11):1441-1445.
20. Frazatti-Gallina N.M., Mourão-Fuches R.M., Paoli R.L., Silva M.L., Miyaki C., Valentini E.J., Raw I., Higashi H.G. Vero-cell rabies vaccine produced using serum-free medium. Vaccine 2004, 23(4):511-517.
21. Budowsky E.I., Smirnov YuA, Shenderovich S.F. Principles of selective inactivation of viral genome. VIII. The influence of beta-propiolactone on immunogenic and protective activities of influenza virus. Vaccine 1993, 11(3):343-348.
22. Srivastava S.K., Barnum D.A. Studies on the immunogenicity of Streptococcus equi vaccines in foals. Can J Comp Med 1985, 49(4):351-356.
23. Brusick D.J. The genetic properties of beta-propiolactone. Mutat Res 1977, 39(3-4):241-255.